JP2015509711A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015509711A5 JP2015509711A5 JP2014557867A JP2014557867A JP2015509711A5 JP 2015509711 A5 JP2015509711 A5 JP 2015509711A5 JP 2014557867 A JP2014557867 A JP 2014557867A JP 2014557867 A JP2014557867 A JP 2014557867A JP 2015509711 A5 JP2015509711 A5 JP 2015509711A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- sequence
- aav
- protein
- factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 claims 36
- 239000013598 vector Substances 0.000 claims 22
- 241000702421 Dependoparvovirus Species 0.000 claims 16
- 241000124008 Mammalia Species 0.000 claims 16
- 102000004169 proteins and genes Human genes 0.000 claims 15
- 108091033319 polynucleotide Proteins 0.000 claims 13
- 102000040430 polynucleotide Human genes 0.000 claims 13
- 239000002157 polynucleotide Substances 0.000 claims 13
- 101710132601 Capsid protein Proteins 0.000 claims 7
- 101710197658 Capsid protein VP1 Proteins 0.000 claims 7
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 claims 7
- 101710108545 Viral protein 1 Proteins 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 241000700584 Simplexvirus Species 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 6
- 208000015181 infectious disease Diseases 0.000 claims 6
- 208000015439 Lysosomal storage disease Diseases 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 102100031176 Retinoid isomerohydrolase Human genes 0.000 claims 5
- 210000000234 capsid Anatomy 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108010054126 retinoid isomerohydrolase Proteins 0.000 claims 5
- 102100037156 Gap junction beta-2 protein Human genes 0.000 claims 4
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 4
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 4
- 150000001413 amino acids Chemical group 0.000 claims 4
- 210000004556 brain Anatomy 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- -1 etc.) Proteins 0.000 claims 4
- 230000006870 function Effects 0.000 claims 4
- 238000010362 genome editing Methods 0.000 claims 4
- 239000003102 growth factor Substances 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 108700028369 Alleles Proteins 0.000 claims 3
- 206010003694 Atrophy Diseases 0.000 claims 3
- 102100022641 Coagulation factor IX Human genes 0.000 claims 3
- 208000031886 HIV Infections Diseases 0.000 claims 3
- 208000037357 HIV infectious disease Diseases 0.000 claims 3
- 208000005176 Hepatitis C Diseases 0.000 claims 3
- 241000725303 Human immunodeficiency virus Species 0.000 claims 3
- 208000036626 Mental retardation Diseases 0.000 claims 3
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 3
- 108700011259 MicroRNAs Proteins 0.000 claims 3
- 102100029081 Proteasome subunit beta type-10 Human genes 0.000 claims 3
- 102100035760 Proteasome subunit beta type-8 Human genes 0.000 claims 3
- 241000725643 Respiratory syncytial virus Species 0.000 claims 3
- 241000714474 Rous sarcoma virus Species 0.000 claims 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 3
- 230000037444 atrophy Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 210000004185 liver Anatomy 0.000 claims 3
- 208000021039 metastatic melanoma Diseases 0.000 claims 3
- 239000002679 microRNA Substances 0.000 claims 3
- 210000004498 neuroglial cell Anatomy 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 230000035897 transcription Effects 0.000 claims 3
- 238000013518 transcription Methods 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 108010046716 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide) Proteins 0.000 claims 2
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 claims 2
- 101150091481 ATP7 gene Proteins 0.000 claims 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 2
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims 2
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims 2
- 208000003200 Adenoma Diseases 0.000 claims 2
- 206010001233 Adenoma benign Diseases 0.000 claims 2
- 102100036664 Adenosine deaminase Human genes 0.000 claims 2
- 102000055025 Adenosine deaminases Human genes 0.000 claims 2
- 101710095342 Apolipoprotein B Proteins 0.000 claims 2
- 102100040202 Apolipoprotein B-100 Human genes 0.000 claims 2
- 208000015508 Ascher syndrome Diseases 0.000 claims 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims 2
- 208000035545 CNGA3-related retinopathy Diseases 0.000 claims 2
- 101100029886 Caenorhabditis elegans lov-1 gene Proteins 0.000 claims 2
- 108010078791 Carrier Proteins Proteins 0.000 claims 2
- 208000006992 Color Vision Defects Diseases 0.000 claims 2
- 206010010356 Congenital anomaly Diseases 0.000 claims 2
- 108010069156 Connexin 26 Proteins 0.000 claims 2
- 102000012437 Copper-Transporting ATPases Human genes 0.000 claims 2
- 108010022637 Copper-Transporting ATPases Proteins 0.000 claims 2
- 241000709675 Coxsackievirus B3 Species 0.000 claims 2
- 102100029142 Cyclic nucleotide-gated cation channel alpha-3 Human genes 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 claims 2
- 102000003849 Cytochrome P450 Human genes 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000000311 Cytosine Deaminase Human genes 0.000 claims 2
- 108010080611 Cytosine Deaminase Proteins 0.000 claims 2
- 206010011878 Deafness Diseases 0.000 claims 2
- 102100029588 Deoxycytidine kinase Human genes 0.000 claims 2
- 108010033174 Deoxycytidine kinase Proteins 0.000 claims 2
- 102000016607 Diphtheria Toxin Human genes 0.000 claims 2
- 108010053187 Diphtheria Toxin Proteins 0.000 claims 2
- 206010059866 Drug resistance Diseases 0.000 claims 2
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 101800003838 Epidermal growth factor Proteins 0.000 claims 2
- 102000003951 Erythropoietin Human genes 0.000 claims 2
- 108090000394 Erythropoietin Proteins 0.000 claims 2
- 108010076282 Factor IX Proteins 0.000 claims 2
- 108010054265 Factor VIIa Proteins 0.000 claims 2
- 108010014173 Factor X Proteins 0.000 claims 2
- 108010071289 Factor XIII Proteins 0.000 claims 2
- 102000013446 GTP Phosphohydrolases Human genes 0.000 claims 2
- 108091006109 GTPases Proteins 0.000 claims 2
- 102100023364 Ganglioside GM2 activator Human genes 0.000 claims 2
- 101710201362 Ganglioside GM2 activator Proteins 0.000 claims 2
- 108010021582 Glucokinase Proteins 0.000 claims 2
- 102000030595 Glucokinase Human genes 0.000 claims 2
- 102000004547 Glucosylceramidase Human genes 0.000 claims 2
- 108010017544 Glucosylceramidase Proteins 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 2
- 101710191387 Guanylate cyclase 2D Proteins 0.000 claims 2
- 102100027685 Hemoglobin subunit alpha Human genes 0.000 claims 2
- 108091005902 Hemoglobin subunit alpha Proteins 0.000 claims 2
- 102100021519 Hemoglobin subunit beta Human genes 0.000 claims 2
- 108091005904 Hemoglobin subunit beta Proteins 0.000 claims 2
- 101000771071 Homo sapiens Cyclic nucleotide-gated cation channel alpha-3 Proteins 0.000 claims 2
- 101000954092 Homo sapiens Gap junction beta-2 protein Proteins 0.000 claims 2
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 claims 2
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 claims 2
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 2
- 102100025947 Insulin-like growth factor II Human genes 0.000 claims 2
- 102000006992 Interferon-alpha Human genes 0.000 claims 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 2
- 102000003996 Interferon-beta Human genes 0.000 claims 2
- 108090000467 Interferon-beta Proteins 0.000 claims 2
- 108010074328 Interferon-gamma Proteins 0.000 claims 2
- 102000008070 Interferon-gamma Human genes 0.000 claims 2
- 102000013462 Interleukin-12 Human genes 0.000 claims 2
- 108010065805 Interleukin-12 Proteins 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 102000004388 Interleukin-4 Human genes 0.000 claims 2
- 108090000978 Interleukin-4 Proteins 0.000 claims 2
- 108010001831 LDL receptors Proteins 0.000 claims 2
- 108010013563 Lipoprotein Lipase Proteins 0.000 claims 2
- 102100022119 Lipoprotein lipase Human genes 0.000 claims 2
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 claims 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 claims 2
- 108010006140 N-sulfoglucosamine sulfohydrolase Proteins 0.000 claims 2
- 102100027661 N-sulphoglucosamine sulphohydrolase Human genes 0.000 claims 2
- 102000015336 Nerve Growth Factor Human genes 0.000 claims 2
- 102000007072 Nerve Growth Factors Human genes 0.000 claims 2
- 102000004132 Ornithine aminotransferases Human genes 0.000 claims 2
- 108090000691 Ornithine aminotransferases Proteins 0.000 claims 2
- 102000007981 Ornithine carbamoyltransferase Human genes 0.000 claims 2
- 101710198224 Ornithine carbamoyltransferase, mitochondrial Proteins 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims 2
- 102100033237 Pro-epidermal growth factor Human genes 0.000 claims 2
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 claims 2
- 101710180553 Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 claims 2
- 108050005569 Proteasome subunit beta type 8 Proteins 0.000 claims 2
- 101710084225 Proteasome subunit beta type-10 Proteins 0.000 claims 2
- 101800004937 Protein C Proteins 0.000 claims 2
- 102000017975 Protein C Human genes 0.000 claims 2
- 101710088575 Rab escort protein 1 Proteins 0.000 claims 2
- 101710108890 Rab proteins geranylgeranyltransferase component A 1 Proteins 0.000 claims 2
- 102100022881 Rab proteins geranylgeranyltransferase component A 1 Human genes 0.000 claims 2
- 208000033626 Renal failure acute Diseases 0.000 claims 2
- 101800001700 Saposin-D Proteins 0.000 claims 2
- 102100026219 Serine/threonine-protein kinase N3 Human genes 0.000 claims 2
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 claims 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims 2
- 102000013275 Somatomedins Human genes 0.000 claims 2
- 102000005890 Spectrin Human genes 0.000 claims 2
- 108010019965 Spectrin Proteins 0.000 claims 2
- 102000011971 Sphingomyelin Phosphodiesterase Human genes 0.000 claims 2
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 claims 2
- 102000005262 Sulfatase Human genes 0.000 claims 2
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 claims 2
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 claims 2
- 102000006601 Thymidine Kinase Human genes 0.000 claims 2
- 108020004440 Thymidine kinase Proteins 0.000 claims 2
- 108010009583 Transforming Growth Factors Proteins 0.000 claims 2
- 102000009618 Transforming Growth Factors Human genes 0.000 claims 2
- 108010039203 Tripeptidyl-Peptidase 1 Proteins 0.000 claims 2
- 102100034197 Tripeptidyl-peptidase 1 Human genes 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 claims 2
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 claims 2
- 102100022356 Tyrosine-protein kinase Mer Human genes 0.000 claims 2
- 102100038413 UDP-N-acetylglucosamine-dolichyl-phosphate N-acetylglucosaminephosphotransferase Human genes 0.000 claims 2
- 108010024501 UDPacetylglucosamine-dolichyl-phosphate acetylglucosamine-1-phosphate transferase Proteins 0.000 claims 2
- 201000001408 X-linked juvenile retinoschisis 1 Diseases 0.000 claims 2
- 208000017441 X-linked retinoschisis Diseases 0.000 claims 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims 2
- 208000002771 achromatopsia 2 Diseases 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 201000011040 acute kidney failure Diseases 0.000 claims 2
- 208000012998 acute renal failure Diseases 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 208000031514 autosomal recessive nonsyndromic hearing loss 1A Diseases 0.000 claims 2
- 230000023555 blood coagulation Effects 0.000 claims 2
- 239000003114 blood coagulation factor Substances 0.000 claims 2
- 229940019700 blood coagulation factors Drugs 0.000 claims 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 claims 2
- 108010018804 c-Mer Tyrosine Kinase Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000015271 coagulation Effects 0.000 claims 2
- 238000005345 coagulation Methods 0.000 claims 2
- 201000007254 color blindness Diseases 0.000 claims 2
- 208000031513 cyst Diseases 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 2
- 230000002950 deficient Effects 0.000 claims 2
- 229940088598 enzyme Drugs 0.000 claims 2
- 229940116977 epidermal growth factor Drugs 0.000 claims 2
- 229940105423 erythropoietin Drugs 0.000 claims 2
- 229960004222 factor ix Drugs 0.000 claims 2
- 229940012414 factor viia Drugs 0.000 claims 2
- 229940012426 factor x Drugs 0.000 claims 2
- 229940012444 factor xiii Drugs 0.000 claims 2
- 108091006104 gene-regulatory proteins Proteins 0.000 claims 2
- 102000034356 gene-regulatory proteins Human genes 0.000 claims 2
- 230000010370 hearing loss Effects 0.000 claims 2
- 231100000888 hearing loss Toxicity 0.000 claims 2
- 208000016354 hearing loss disease Diseases 0.000 claims 2
- 210000003494 hepatocyte Anatomy 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 230000002163 immunogen Effects 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 229960003130 interferon gamma Drugs 0.000 claims 2
- 229940117681 interleukin-12 Drugs 0.000 claims 2
- 229940028885 interleukin-4 Drugs 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 229910052751 metal Inorganic materials 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- 229940053128 nerve growth factor Drugs 0.000 claims 2
- 239000003900 neurotrophic factor Substances 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 108010056274 polo-like kinase 1 Proteins 0.000 claims 2
- 208000014081 polyp of colon Diseases 0.000 claims 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 2
- 229960000856 protein c Drugs 0.000 claims 2
- 108010061151 protein kinase N Proteins 0.000 claims 2
- 230000002207 retinal effect Effects 0.000 claims 2
- 201000007714 retinoschisis Diseases 0.000 claims 2
- 108010047866 ribonucleotide reductase M2 Proteins 0.000 claims 2
- 150000003408 sphingolipids Chemical class 0.000 claims 2
- 108060007951 sulfatase Proteins 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 230000003614 tolerogenic effect Effects 0.000 claims 2
- 239000002753 trypsin inhibitor Substances 0.000 claims 2
- 102000003390 tumor necrosis factor Human genes 0.000 claims 2
- 239000000225 tumor suppressor protein Substances 0.000 claims 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 2
- 108700026220 vif Genes Proteins 0.000 claims 2
- 230000001018 virulence Effects 0.000 claims 2
- 239000013607 AAV vector Substances 0.000 claims 1
- 102100024378 AF4/FMR2 family member 2 Human genes 0.000 claims 1
- 241001655883 Adeno-associated virus - 1 Species 0.000 claims 1
- 241000202702 Adeno-associated virus - 3 Species 0.000 claims 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 claims 1
- 241001634120 Adeno-associated virus - 5 Species 0.000 claims 1
- 241000972680 Adeno-associated virus - 6 Species 0.000 claims 1
- 241001164823 Adeno-associated virus - 7 Species 0.000 claims 1
- 241000649045 Adeno-associated virus 10 Species 0.000 claims 1
- 241000649046 Adeno-associated virus 11 Species 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 102100032187 Androgen receptor Human genes 0.000 claims 1
- 108020005544 Antisense RNA Proteins 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 101710147490 Ataxin-8 Proteins 0.000 claims 1
- 102100026565 Ataxin-8 Human genes 0.000 claims 1
- 102000014461 Ataxins Human genes 0.000 claims 1
- 108010078286 Ataxins Proteins 0.000 claims 1
- 102000004321 Atrophin-1 Human genes 0.000 claims 1
- 102100020741 Atrophin-1 Human genes 0.000 claims 1
- 108090000806 Atrophin-1 Proteins 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 102100039705 Beta-2 adrenergic receptor Human genes 0.000 claims 1
- 102000015735 Beta-catenin Human genes 0.000 claims 1
- 108060000903 Beta-catenin Proteins 0.000 claims 1
- 208000019838 Blood disease Diseases 0.000 claims 1
- 208000029402 Bulbospinal muscular atrophy Diseases 0.000 claims 1
- 108091008927 CC chemokine receptors Proteins 0.000 claims 1
- 102000005674 CCR Receptors Human genes 0.000 claims 1
- 102000003922 Calcium Channels Human genes 0.000 claims 1
- 108090000312 Calcium Channels Proteins 0.000 claims 1
- 102000004046 Caspase-2 Human genes 0.000 claims 1
- 108090000552 Caspase-2 Proteins 0.000 claims 1
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 1
- 102000009410 Chemokine receptor Human genes 0.000 claims 1
- 108050000299 Chemokine receptor Proteins 0.000 claims 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 102100023804 Coagulation factor VII Human genes 0.000 claims 1
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 1
- 206010010099 Combined immunodeficiency Diseases 0.000 claims 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 1
- 102100026139 DNA damage-inducible transcript 4 protein Human genes 0.000 claims 1
- 102000002148 Diacylglycerol O-acyltransferase Human genes 0.000 claims 1
- 108010001348 Diacylglycerol O-acyltransferase Proteins 0.000 claims 1
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 108010023321 Factor VII Proteins 0.000 claims 1
- 108010054218 Factor VIII Proteins 0.000 claims 1
- 102000001690 Factor VIII Human genes 0.000 claims 1
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 1
- 241000711950 Filoviridae Species 0.000 claims 1
- 108010032606 Fragile X Mental Retardation Protein Proteins 0.000 claims 1
- 208000001914 Fragile X syndrome Diseases 0.000 claims 1
- 102000003869 Frataxin Human genes 0.000 claims 1
- 108090000217 Frataxin Proteins 0.000 claims 1
- 208000024412 Friedreich ataxia Diseases 0.000 claims 1
- 102100035233 Furin Human genes 0.000 claims 1
- 108090001126 Furin Proteins 0.000 claims 1
- 208000015872 Gaucher disease Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000018565 Hemochromatosis Diseases 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 206010019695 Hepatic neoplasm Diseases 0.000 claims 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 1
- 101000833172 Homo sapiens AF4/FMR2 family member 2 Proteins 0.000 claims 1
- 101000873082 Homo sapiens Ataxin-1 Proteins 0.000 claims 1
- 101000895114 Homo sapiens Ataxin-2 Proteins 0.000 claims 1
- 101000895100 Homo sapiens Ataxin-3 Proteins 0.000 claims 1
- 101000895103 Homo sapiens Ataxin-7 Proteins 0.000 claims 1
- 101000785083 Homo sapiens Atrophin-1 Proteins 0.000 claims 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 1
- 101000912753 Homo sapiens DNA damage-inducible transcript 4 protein Proteins 0.000 claims 1
- 101001124792 Homo sapiens Proteasome subunit beta type-10 Proteins 0.000 claims 1
- 101001136986 Homo sapiens Proteasome subunit beta type-8 Proteins 0.000 claims 1
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 claims 1
- 101000701517 Homo sapiens Putative protein ATXN8OS Proteins 0.000 claims 1
- 101000662686 Homo sapiens Torsin-1A Proteins 0.000 claims 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 241000712431 Influenza A virus Species 0.000 claims 1
- 102000011782 Keratins Human genes 0.000 claims 1
- 108010076876 Keratins Proteins 0.000 claims 1
- 102000010638 Kinesin Human genes 0.000 claims 1
- 108010063296 Kinesin Proteins 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000003221 Lysosomal acid lipase deficiency Diseases 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- 208000008948 Menkes Kinky Hair Syndrome Diseases 0.000 claims 1
- 208000012583 Menkes disease Diseases 0.000 claims 1
- 206010056886 Mucopolysaccharidosis I Diseases 0.000 claims 1
- 108010021466 Mutant Proteins Proteins 0.000 claims 1
- 102000008300 Mutant Proteins Human genes 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 claims 1
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 claims 1
- 101710096541 Proteasome subunit beta Proteins 0.000 claims 1
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 claims 1
- 108010029485 Protein Isoforms Proteins 0.000 claims 1
- 102000001708 Protein Isoforms Human genes 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 102000006478 Protein Phosphatase 2 Human genes 0.000 claims 1
- 102100030469 Putative protein ATXN8OS Human genes 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 108091027981 Response element Proteins 0.000 claims 1
- 201000007737 Retinal degeneration Diseases 0.000 claims 1
- 102100040756 Rhodopsin Human genes 0.000 claims 1
- 108090000820 Rhodopsin Proteins 0.000 claims 1
- 241000315672 SARS coronavirus Species 0.000 claims 1
- 101710189648 Serine/threonine-protein phosphatase Proteins 0.000 claims 1
- 108091027967 Small hairpin RNA Proteins 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 1
- 102100023532 Synaptic functional regulator FMR1 Human genes 0.000 claims 1
- 102000006467 TATA-Box Binding Protein Human genes 0.000 claims 1
- 108010044281 TATA-Box Binding Protein Proteins 0.000 claims 1
- 208000002903 Thalassemia Diseases 0.000 claims 1
- 102100037454 Torsin-1A Human genes 0.000 claims 1
- 108091023040 Transcription factor Proteins 0.000 claims 1
- 102000040945 Transcription factor Human genes 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims 1
- 208000018839 Wilson disease Diseases 0.000 claims 1
- 210000001766 X chromosome Anatomy 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 201000009628 adenosine deaminase deficiency Diseases 0.000 claims 1
- 108010080146 androgen receptors Proteins 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims 1
- 208000036556 autosomal recessive T cell-negative B cell-negative NK cell-negative due to adenosine deaminase deficiency severe combined immunodeficiency Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 210000003591 cerebellar nuclei Anatomy 0.000 claims 1
- 210000003161 choroid Anatomy 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- 239000010949 copper Substances 0.000 claims 1
- 101150074488 ddit4 gene Proteins 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 238000009826 distribution Methods 0.000 claims 1
- 210000003890 endocrine cell Anatomy 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 210000000594 epithelial cell of lung Anatomy 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 229940012413 factor vii Drugs 0.000 claims 1
- 229960000301 factor viii Drugs 0.000 claims 1
- 230000030279 gene silencing Effects 0.000 claims 1
- 102000054767 gene variant Human genes 0.000 claims 1
- 208000007345 glycogen storage disease Diseases 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 208000018706 hematopoietic system disease Diseases 0.000 claims 1
- 208000009429 hemophilia B Diseases 0.000 claims 1
- 208000031169 hemorrhagic disease Diseases 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 102000056417 human ATXN1 Human genes 0.000 claims 1
- 102000056418 human ATXN2 Human genes 0.000 claims 1
- 102000056336 human ATXN3 Human genes 0.000 claims 1
- 102000056451 human ATXN7 Human genes 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 230000004957 immunoregulator effect Effects 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000002132 lysosomal effect Effects 0.000 claims 1
- 210000003712 lysosome Anatomy 0.000 claims 1
- 230000001868 lysosomic effect Effects 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 210000002894 multi-fate stem cell Anatomy 0.000 claims 1
- 230000003274 myotonic effect Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000004768 organ dysfunction Effects 0.000 claims 1
- 230000001898 pallidal effect Effects 0.000 claims 1
- 210000004738 parenchymal cell Anatomy 0.000 claims 1
- 230000008506 pathogenesis Effects 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 210000001778 pluripotent stem cell Anatomy 0.000 claims 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 210000000463 red nucleus Anatomy 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 claims 1
- 210000002955 secretory cell Anatomy 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 210000003014 totipotent stem cell Anatomy 0.000 claims 1
- 238000002627 tracheal intubation Methods 0.000 claims 1
- 230000010415 tropism Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261600415P | 2012-02-17 | 2012-02-17 | |
| US61/600,415 | 2012-02-17 | ||
| PCT/US2013/026695 WO2013123503A1 (en) | 2012-02-17 | 2013-02-19 | Aav vector compositions and methods for gene transfer to cells, organs and tissues |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018076881A Division JP2018121655A (ja) | 2012-02-17 | 2018-04-12 | Ａａｖベクター成分、及び、細胞、臓器並びに組織への遺伝子導入のための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015509711A JP2015509711A (ja) | 2015-04-02 |
| JP2015509711A5 true JP2015509711A5 (https=) | 2016-04-07 |
| JP6373763B2 JP6373763B2 (ja) | 2018-08-22 |
Family
ID=48984822
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014557867A Active JP6373763B2 (ja) | 2012-02-17 | 2013-02-19 | Ａａｖベクター成分、及び、細胞、臓器並びに組織への遺伝子導入のための方法 |
| JP2018076881A Pending JP2018121655A (ja) | 2012-02-17 | 2018-04-12 | Ａａｖベクター成分、及び、細胞、臓器並びに組織への遺伝子導入のための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018076881A Pending JP2018121655A (ja) | 2012-02-17 | 2018-04-12 | Ａａｖベクター成分、及び、細胞、臓器並びに組織への遺伝子導入のための方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20150111955A1 (https=) |
| EP (1) | EP2814958B1 (https=) |
| JP (2) | JP6373763B2 (https=) |
| KR (1) | KR102057540B1 (https=) |
| CN (1) | CN104520428B (https=) |
| AU (1) | AU2013221212B2 (https=) |
| BR (1) | BR112014020325A2 (https=) |
| CA (1) | CA2864879C (https=) |
| CL (1) | CL2014002198A1 (https=) |
| ES (1) | ES2752191T3 (https=) |
| IL (1) | IL234148B (https=) |
| MX (1) | MX367100B (https=) |
| RU (1) | RU2653444C2 (https=) |
| SG (1) | SG11201404956PA (https=) |
| WO (1) | WO2013123503A1 (https=) |
| ZA (1) | ZA201406065B (https=) |
Families Citing this family (190)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX359371B (es) | 2001-11-13 | 2018-09-25 | Univ Pennsylvania | Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo. |
| US9217155B2 (en) | 2008-05-28 | 2015-12-22 | University Of Massachusetts | Isolation of novel AAV'S and uses thereof |
| US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
| EP2561073B1 (en) | 2010-04-23 | 2016-08-24 | University of Massachusetts | Cns targeting aav vectors and methods of use thereof |
| US9546369B2 (en) | 2010-04-23 | 2017-01-17 | University Of Massachusetts | Multicistronic expression constructs |
| MX374963B (es) | 2011-04-29 | 2025-03-06 | Selecta Biosciences Inc | Nanoportadores sintéticos tolerogénicos para reducir las respuestas de anticuerpos. |
| HK1202434A1 (en) | 2011-11-22 | 2015-10-02 | The Children's Hospital Of Philadelphia | Virus vectors for highly efficient transgene delivery |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| US9539307B2 (en) | 2012-09-17 | 2017-01-10 | The Research Institute At Nationwide Children's Hospital | Compositions and methods for treating amyotrophic lateral sclerosis |
| HK1220488A1 (zh) | 2013-03-15 | 2017-05-05 | The Children's Hospital Of Philadelphia | 含有填充者/填充物多核苷酸序列的载体及其使用方法 |
| BR122020023215B1 (pt) | 2013-05-03 | 2022-11-22 | Selecta Biosciences, Inc | Composição e kit de nanocarreadores sintéticos tolerogênicos para reduzir ou prevenir anafilaxia em resposta a um antígeno não alergênico |
| IL297919A (en) * | 2013-07-22 | 2023-01-01 | Childrens Hospital Philadelphia | Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| US9725719B2 (en) | 2013-11-05 | 2017-08-08 | The Research Institute At Nationwide Children's Hospital | Compositions and methods for inhibiting NF-κB and SOD-1 to treat amyotrophic lateral sclerosis |
| US10072251B2 (en) | 2014-02-19 | 2018-09-11 | University Of Massachusetts | Recombinant AAVS having useful transcytosis properties |
| CA2942515C (en) | 2014-03-18 | 2025-12-09 | University Of Massachusetts | Raav-based compositions and methods for treating amyotrophic lateral sclerosis |
| PL3628334T3 (pl) * | 2014-03-21 | 2023-12-18 | Genzyme Corporation | Terapia genowa w retinopatii barwnikowej |
| WO2015164786A1 (en) | 2014-04-25 | 2015-10-29 | University Of Massachusetts | Recombinant aav vectors useful for reducing immunity against transgene products |
| EP3134431B1 (en) | 2014-04-25 | 2021-04-07 | The Trustees Of The University Of Pennsylvania | Ldlr variants and their use in compositions for reducing cholesterol levels |
| WO2015187825A2 (en) | 2014-06-03 | 2015-12-10 | University Of Massachusetts | Compositions and methods for modulating dysferlin expression |
| EP3151866B1 (en) | 2014-06-09 | 2023-03-08 | Voyager Therapeutics, Inc. | Chimeric capsids |
| CN105396143B (zh) * | 2014-09-01 | 2020-06-26 | 江苏命码生物科技有限公司 | 埃博拉病毒特异性的miRNA以及通过miRNA抑制埃博拉病毒的方法 |
| JP7242180B2 (ja) * | 2014-09-07 | 2023-03-20 | セレクタ バイオサイエンシーズ インコーポレーテッド | 抗ウイルス導入ベクター免疫応答を減弱化するための方法および組成物 |
| US10370432B2 (en) | 2014-10-03 | 2019-08-06 | University Of Massachusetts | Heterologous targeting peptide grafted AAVS |
| EP3200830B1 (en) | 2014-10-03 | 2020-09-09 | University of Massachusetts | High efficiency library-identified aav vectors |
| CN107073051B (zh) | 2014-10-21 | 2021-08-24 | 马萨诸塞大学 | 重组aav变体及其用途 |
| RU2716991C2 (ru) | 2014-11-05 | 2020-03-17 | Вояджер Терапьютикс, Инк. | Полинуклеотиды aadc для лечения болезни паркинсона |
| GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
| KR20230145206A (ko) | 2014-11-14 | 2023-10-17 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
| WO2016077687A1 (en) | 2014-11-14 | 2016-05-19 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| US11697825B2 (en) | 2014-12-12 | 2023-07-11 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scAAV |
| EP3256170B1 (en) | 2015-02-13 | 2020-09-23 | University of Massachusetts | Compositions and methods for transient delivery of nucleases |
| US11046955B2 (en) | 2015-04-24 | 2021-06-29 | University Of Massachusetts | Modified AAV constructs and uses thereof |
| ES2799515T3 (es) | 2015-05-22 | 2020-12-18 | Dmitry Dmitrievich Genkin | ADN extracelular como una diana terapéutica en la neurodegeneración |
| MX390848B (es) | 2015-06-23 | 2025-03-21 | Childrens Hospital Philadelphia | Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos. |
| CN107921067A (zh) * | 2015-07-10 | 2018-04-17 | 杜克大学 | 用于治疗疼痛的方法 |
| IL258005B2 (en) | 2015-09-17 | 2025-01-01 | Res Inst Nationwide Childrens Hospital | Methods and materials for gene therapy for beta-4,1-N-acetylgalactosaminyltransferase 2 |
| TW202446416A (zh) | 2015-09-24 | 2024-12-01 | 美商拜奧馬林製藥公司 | 腺相關病毒因子viii載體、相關病毒粒子及包含其之治療調配物 |
| ES2879400T3 (es) * | 2015-10-21 | 2021-11-22 | Us Health | ADNc de ATP7A de tamaño reducido con codones optimizados y usos para el tratamiento de trastornos del transporte de cobre |
| EP3364997B1 (en) | 2015-10-22 | 2024-01-17 | University of Massachusetts | Aspartoacylase gene therapy in the treatment of canavan disease |
| WO2017070516A1 (en) | 2015-10-22 | 2017-04-27 | University Of Massachusetts | Prostate-targeting adeno-associated virus serotype vectors |
| EA202190827A1 (ru) | 2015-11-13 | 2021-11-30 | Баксалта Инкорпорейтед | Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a |
| CA3005565A1 (en) | 2015-11-13 | 2017-05-18 | Baxalta Incorporated | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a |
| KR102877920B1 (ko) | 2015-11-16 | 2025-10-30 | 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 | 티틴-기반 근증 및 다른 티틴성병증의 치료를 위한 물질 및 방법 |
| EP3384015A4 (en) * | 2015-12-01 | 2019-05-29 | Spark Therapeutics, Inc. | SCALABLE PROCESS FOR THE PREPARATION OF A RECOMBINANT ADENO ASSOCIATED VIRAL VECTOR IN A SERUM-FREE SUSPENSION CELL CULTURE SYSTEM SUITABLE FOR THE CLINICAL APPLICATION |
| EP3384035A4 (en) | 2015-12-02 | 2019-08-07 | Voyager Therapeutics, Inc. | ASSAYS FOR THE DETECTION OF AAV-NEUTRALIZING ANTIBODIES |
| AU2016366560A1 (en) * | 2015-12-11 | 2018-06-28 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating familial hypercholesterolemia |
| CA3011939A1 (en) | 2016-02-02 | 2017-08-10 | University Of Massachusetts | Method to enhance the efficiency of systemic aav gene delivery to the central nervous system |
| CA3012344A1 (en) | 2016-02-12 | 2017-08-17 | University Of Massachusetts | Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization |
| WO2017173043A1 (en) * | 2016-03-30 | 2017-10-05 | Spark Therapeutics, Inc. | Cell line for recombinant protein and/or viral vector production |
| US11207426B2 (en) | 2016-04-05 | 2021-12-28 | University Of Massachusetts | Compositions and methods for selective inhibition of grainyhead-like protein expression |
| LT3442600T (lt) * | 2016-04-15 | 2024-05-27 | Research Institute At Nationwide Children's Hospital | Su adeno virusu susijusio viruso vektoriaus iš β-sarkoglikano ir mikro- rnr-29 pristatymas ir raumenų distrofijos gydymas |
| US11413356B2 (en) | 2016-04-15 | 2022-08-16 | University Of Massachusetts | Methods and compositions for treating metabolic imbalance |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| US11364308B2 (en) | 2016-05-13 | 2022-06-21 | 4D Molecular Therapeutics Inc. | Adeno-associated virus variant capsids and methods of use thereof |
| KR102427379B1 (ko) | 2016-05-18 | 2022-08-02 | 보이저 테라퓨틱스, 인크. | 헌팅톤 질환을 치료하기 위한 조성물 및 방법 |
| KR20240056729A (ko) | 2016-05-18 | 2024-04-30 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
| US11882815B2 (en) | 2016-06-15 | 2024-01-30 | University Of Massachusetts | Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells |
| WO2018022511A1 (en) | 2016-07-25 | 2018-02-01 | The Trustees Of The University Of Pennsylvania | Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof |
| IL305149A (en) | 2016-07-26 | 2023-10-01 | Biomarin Pharm Inc | Novel adeno-associated virus capsid proteins |
| EP3510161A4 (en) | 2016-08-23 | 2020-04-22 | Akouos, Inc. | COMPOSITIONS AND METHODS FOR TREATING PERSONAL HEARING LOSS IN A PERSON |
| CN106344932B (zh) * | 2016-08-26 | 2019-12-27 | 首都医科大学附属北京同仁医院 | 一种用于提高视网膜退行性疾病基因治疗效果的组合物及其应用 |
| WO2018044933A1 (en) | 2016-08-30 | 2018-03-08 | The Regents Of The University Of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
| US10457940B2 (en) | 2016-09-22 | 2019-10-29 | University Of Massachusetts | AAV treatment of Huntington's disease |
| AU2017341849B2 (en) | 2016-10-13 | 2024-03-21 | University Of Massachusetts | AAV capsid designs |
| WO2018082093A1 (en) * | 2016-11-07 | 2018-05-11 | Wuhan Institute Of Virology, Chinese Academy Of Sciences | Anterograde monosynaptic transneuronal tracer system |
| BR112019013245A2 (pt) | 2016-12-30 | 2020-02-11 | The Trustees Of The University Of Pennsylvania | Terapia gênica para tratamento da doença de wilson |
| JP7215716B2 (ja) | 2017-01-13 | 2023-01-31 | 学校法人自治医科大学 | 肝臓ゲノム上の凝固関連因子遺伝子を破壊するためのａａｖベクター |
| JP2020510648A (ja) | 2017-02-20 | 2020-04-09 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 家族性高コレステロール血症を処置するための遺伝子治療 |
| JOP20190200A1 (ar) * | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | تركيبات نافعة في معالجة ضمور العضل النخاعي |
| EP3589307B1 (en) * | 2017-02-28 | 2022-02-16 | The Penn State Research Foundation | Regenerating functional neurons for treatment of neural injury caused by disruption of blood flow |
| RU2019130004A (ru) * | 2017-03-01 | 2021-04-01 | Зе Трастис Оф Зе Юниверсити Оф Пеннсильвания | Генная терапия при глазных заболеваниях |
| ES3036482T3 (en) | 2017-03-11 | 2025-09-19 | Cartesian Therapeutics Inc | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| EP3596112A2 (en) | 2017-03-17 | 2020-01-22 | Newcastle University | Adeno-associated virus vector delivery of a fragment of micro-dystrophin to treat muscular dystrophy |
| JP7676111B2 (ja) * | 2017-03-17 | 2025-05-14 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | 筋ジストロフィーを治療するための筋肉特異的マイクロジストロフィンのアデノ随伴ウイルスベクター送達 |
| MX2019011772A (es) | 2017-04-03 | 2020-01-09 | Encoded Therapeutics Inc | Expresion transgenica selectiva de tejidos. |
| JP2020518259A (ja) | 2017-05-05 | 2020-06-25 | ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ハンチントン病治療組成物および方法 |
| JP2020518258A (ja) | 2017-05-05 | 2020-06-25 | ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 筋萎縮性側索硬化症（ａｌｓ）治療組成物および方法 |
| US11859179B2 (en) | 2017-05-09 | 2024-01-02 | University Of Massachusetts | Methods of treating amyotrophic lateral sclerosis (ALS) |
| AU2018269050A1 (en) * | 2017-05-19 | 2020-01-16 | Encoded Therapeutics, Inc. | High activity regulatory elements |
| CN110945127B (zh) | 2017-05-22 | 2024-07-12 | 武田药品工业株式会社 | 用于血友病b的基因疗法的编码具有增加的表达的重组fix的病毒载体 |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| CA3070087A1 (en) | 2017-07-17 | 2019-01-24 | Voyager Therapeutics, Inc. | Trajectory array guide system |
| US20200164008A1 (en) * | 2017-07-17 | 2020-05-28 | Spark Therapeutics, Inc. | Apheresis methods and uses |
| EP3808849A1 (en) | 2017-08-03 | 2021-04-21 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
| NZ762100A (en) | 2017-08-09 | 2025-12-19 | Bioverativ Therapeutics Inc | Nucleic acid molecules and uses thereof |
| AU2018329741B2 (en) | 2017-09-08 | 2025-02-20 | Poseida Therapeutics, Inc. | Compositions and methods for chimeric ligand receptor (CLR)-mediated conditional gene expression |
| RU2770922C2 (ru) | 2017-09-20 | 2022-04-25 | 4Д Молекьюлар Терапьютикс Инк. | Капсиды вариантов аденоассоциированных вирусов и методы их применения |
| CN111448321A (zh) | 2017-09-22 | 2020-07-24 | 马萨诸塞大学 | Sod1双表达载体及其用途 |
| AU2018338728B2 (en) | 2017-09-29 | 2025-01-02 | Centre National De La Recherche Scientifique (Cnrs) | Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery |
| EP3697908A1 (en) | 2017-10-16 | 2020-08-26 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
| TW202413649A (zh) | 2017-10-16 | 2024-04-01 | 美商航海家醫療公司 | 肌萎縮性脊髓側索硬化症(als)之治療 |
| CN107760719B (zh) * | 2017-10-24 | 2020-09-22 | 北京领柯生物科技有限公司 | 柯萨奇病毒在过继免疫基因递送系统中的应用 |
| CN111770999A (zh) | 2017-11-27 | 2020-10-13 | 4D分子治疗有限公司 | 腺相关病毒变体衣壳和用于抑制血管生成的应用 |
| EP3717505A4 (en) | 2017-12-01 | 2021-12-01 | Encoded Therapeutics, Inc. | GENENICALLY MODIFIED DNA-BINDING PROTEINS |
| EP3728568A4 (en) | 2017-12-19 | 2021-10-06 | The University of North Carolina at Chapel Hill | METHODS AND COMPOSITIONS FOR DELIVERING VIRAL VECTORS BY THE BLOOD-BRAIN BARRIER |
| CA3086046C (en) | 2017-12-29 | 2023-02-21 | Helixmith Co., Ltd. | Adeno-associated virus (aav) vector having hybrid hgf gene introduced thereto |
| AU2019209770B2 (en) | 2018-01-16 | 2025-07-31 | Cls Therapeutics Limited | Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity |
| AR114350A1 (es) | 2018-01-31 | 2020-08-26 | Res Institute At Nationwide ChildrenS Hospital | Terapia genética para la distrofia muscular de cinturas del tipo 2c |
| US10610606B2 (en) | 2018-02-01 | 2020-04-07 | Homology Medicines, Inc. | Adeno-associated virus compositions for PAH gene transfer and methods of use thereof |
| US20190256867A1 (en) | 2018-02-01 | 2019-08-22 | Homology Medicines, Inc. | Adeno-associated virus compositions for restoring pah gene function and methods of use thereof |
| JP7244547B2 (ja) | 2018-02-19 | 2023-03-22 | ホモロジー・メディシンズ・インコーポレイテッド | Ｆ８遺伝子機能を回復させるためのアデノ随伴ウイルス組成物及びその使用の方法 |
| MA51353B1 (fr) | 2018-04-05 | 2022-09-30 | Univ Sorbonne | Sérotype du virus adéno-associé recombinant hybride entre aav9 et aavrh74 possédant un tropisme hépatique réduit |
| MX2020011386A (es) | 2018-04-27 | 2021-01-29 | Spacecraft Seven Llc | Terapia genica para la degeneracion del snc. |
| TW202016314A (zh) | 2018-05-09 | 2020-05-01 | 美商拜奧馬林製藥公司 | 治療苯丙酮尿症之方法 |
| TW202005978A (zh) | 2018-05-14 | 2020-02-01 | 美商拜奧馬林製藥公司 | 新穎肝靶向腺相關病毒載體 |
| KR20210019996A (ko) | 2018-05-15 | 2021-02-23 | 보이저 테라퓨틱스, 인크. | 파킨슨병의 치료를 위한 조성물 및 방법 |
| WO2019236995A1 (en) | 2018-06-08 | 2019-12-12 | University Of Massachusetts | Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells |
| MY208145A (en) | 2018-06-18 | 2025-04-18 | Res Inst Nationwide Childrens Hospital | Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy |
| KR20210028162A (ko) | 2018-06-29 | 2021-03-11 | 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 | 지대근 이영양증 2a형을 치료하기 위한 재조합 아데노 연관 바이러스 생성물 및 방법 |
| US12091675B2 (en) | 2018-07-16 | 2024-09-17 | Takeda Pharmaceutical Company Limited | Gene therapy of hemophilia a using viral vectors encoding recombinant FVIII variants with increased expression |
| EP3833766A1 (en) | 2018-08-09 | 2021-06-16 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof for non-viral gene therapy |
| US20220010333A1 (en) * | 2018-09-06 | 2022-01-13 | The Regents Of The University Of California | Rna and dna base editing via engineered adar recruitment |
| EP3856762A1 (en) | 2018-09-28 | 2021-08-04 | Voyager Therapeutics, Inc. | Frataxin expression constructs having engineered promoters and methods of use thereof |
| US20220089670A1 (en) * | 2018-12-28 | 2022-03-24 | University Of Rochester | Gene Therapy for BEST1 Dominant Mutations |
| DK3906066T5 (da) * | 2019-01-04 | 2024-08-05 | Ultragenyx Pharmaceutical Inc | Geneterapikonstruktioner til behandling af wilsons sygdom |
| TWI851647B (zh) | 2019-01-16 | 2024-08-11 | 日商武田藥品工業股份有限公司 | 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體 |
| BR112021015751A2 (pt) * | 2019-02-12 | 2022-02-08 | Spacecraft Seven Llc | Vetores de terapia genética para tratamento da doença de danon |
| SG11202108044YA (en) | 2019-02-25 | 2021-09-29 | Novartis Ag | Compositions and methods to treat bietti crystalline dystrophy |
| US20220154211A1 (en) | 2019-02-25 | 2022-05-19 | Novartis Ag | Compositions and methods to treat bietti crystalline dystrophy |
| AU2020229340A1 (en) | 2019-02-26 | 2021-09-16 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus vector delivery of B-sarcoglycan and the treatment of muscular dystrophy |
| SG11202109362XA (en) | 2019-02-28 | 2021-09-29 | Encoded Therapeutics Inc | Compositions and methods for treating laminopathies |
| CN109999182B (zh) * | 2019-03-29 | 2023-03-07 | 四川大学华西医院 | 凝血因子在制备抗肿瘤药物中的应用 |
| MX2021014226A (es) * | 2019-05-20 | 2022-01-06 | BioNTech SE | Arn terapeutico para cancer de ovario. |
| PL3976798T3 (pl) | 2019-05-29 | 2026-04-07 | Encoded Therapeutics, Inc. | Kompozycje i sposoby selektywnej regulacji genów |
| AU2020287627A1 (en) | 2019-06-04 | 2021-11-18 | Selecta Biosciences, Inc. | Formulations and doses of PEGylated uricase |
| CA3140685A1 (en) * | 2019-06-10 | 2020-12-17 | Vijay G. Sankaran | Compositions and methods for the treatment of dba using gata1 gene therapy |
| RS65421B1 (sr) | 2019-08-21 | 2024-05-31 | Res Inst Nationwide Childrens Hospital | Isporuka adeno-asociranog virusnog vektora alfa-sarkoglikana i lečenje mišićne distrofije |
| EP4022057A1 (en) | 2019-08-27 | 2022-07-06 | Vertex Pharmaceuticals Incorporated | Compositions and methods for treatment of disorders associated with repetitive dna |
| US20220347318A1 (en) * | 2019-09-25 | 2022-11-03 | University Of Utah Research Foundation | Methods and compositions for the expression of constitutively active rap1a from a vmd2 promoter |
| AU2020356962A1 (en) * | 2019-10-02 | 2022-04-14 | Sangamo Therapeutics, Inc. | Zinc finger protein transcription factors for repressing alpha-synuclein expression |
| KR20220130093A (ko) * | 2019-10-30 | 2022-09-26 | 데시벨 테라퓨틱스, 인크. | 오토펄린 듀얼 벡터 시스템을 사용한 감각신경성 난청을 치료하기 위한 조성물 및 방법 |
| TWI902721B (zh) * | 2019-11-04 | 2025-11-01 | 美商迪賽博治療公司 | 前庭支持細胞啟動子及其用途 |
| WO2021096927A1 (en) * | 2019-11-13 | 2021-05-20 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Compositions and uses thereof for treating, prognosing and diagnosing pulmonary hypertension |
| JP2023503850A (ja) | 2019-11-14 | 2023-02-01 | バイオマリン ファーマシューティカル インコーポレイテッド | 肝臓特異的遺伝子療法ベクターによる遺伝性血管浮腫の治療 |
| US20220409745A1 (en) * | 2019-11-19 | 2022-12-29 | The Regents Of The University Of California | Compositions and methods of using engineered fusion proteins that bind g4c2 human repeats |
| IL293012A (en) * | 2019-11-20 | 2022-07-01 | Bavarian Nordic As | Medicinal uses of 4-1bbl modified ankara virus vaccinia ((recombinant mva |
| AU2020388637A1 (en) * | 2019-11-21 | 2022-07-07 | Remedium Bio, Inc. | Growth factor restoration |
| AU2020395327A1 (en) * | 2019-12-05 | 2022-07-21 | Cornell University | Stabilization of retromer for the treatment of Alzheimer's disease and other neurodegenerative disorders |
| WO2021119538A1 (en) * | 2019-12-11 | 2021-06-17 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods for manufacture and uses thereof |
| JP7846007B2 (ja) * | 2019-12-18 | 2026-04-14 | ノバルティス アーゲー | 異常ヘモグロビン症の治療用組成物及び方法 |
| GB201918879D0 (en) * | 2019-12-19 | 2020-02-05 | Ucl Business Ltd | Treatment of chronic pain |
| CN113025618B (zh) * | 2019-12-24 | 2024-02-06 | 朗信启昇(苏州)生物制药有限公司 | 一种x连锁遗传性视网膜劈裂症的基因治疗方案与应用 |
| TW202140791A (zh) | 2020-01-13 | 2021-11-01 | 美商霍蒙拉奇醫藥公司 | 治療苯酮尿症之方法 |
| JP7703543B2 (ja) * | 2020-01-17 | 2025-07-07 | ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Ｃｒｘ常染色体優性網膜症の処置のための遺伝子治療 |
| KR20220157944A (ko) | 2020-02-21 | 2022-11-29 | 아카우오스, 인크. | 인간 대상체에서 비-연령-연관 청각 장애를 치료하기 위한 조성물 및 방법 |
| EP4114952A4 (en) * | 2020-03-05 | 2024-05-08 | Board of Regents of the University of Nebraska | Crispr/cas9 system for multistrain hiv-1 treatment |
| WO2021183755A1 (en) * | 2020-03-11 | 2021-09-16 | City Of Hope | Dual-targeting chimeric antigen receptor modified t cells comprising il-13 and chlorotoxin for cancer treatment |
| TW202144575A (zh) | 2020-04-03 | 2021-12-01 | 美商拜奧馬林製藥公司 | 使用ａａｖ及治療調配物之苯酮尿症治療 |
| TW202208632A (zh) | 2020-05-27 | 2022-03-01 | 美商同源醫藥公司 | 用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法 |
| US12391745B2 (en) | 2020-06-15 | 2025-08-19 | Sarepta Therapeutics, Inc. | Adeno-associated virus antibodies and fragments thereof |
| US20230256117A1 (en) * | 2020-06-19 | 2023-08-17 | Genethon | Gene therapy expression system allowing an adequate expression in the muscles and in the heart of sgcg |
| JP2023532923A (ja) * | 2020-06-30 | 2023-08-01 | チルドレンズ ナショナル メディカル センター | 骨格筋線維の修復を改善するためのリコンビナントヒト酸性スフィンゴミエリナーゼの使用 |
| CN111500635B (zh) * | 2020-07-02 | 2020-10-09 | 北京大学第三医院（北京大学第三临床医学院） | 一种包含携带核酸分子的载体的试剂盒 |
| CN116333984A (zh) * | 2020-07-14 | 2023-06-27 | 广州泛恩生物科技有限公司 | 基于galnt2阳性t细胞的用于杀伤肿瘤的tcr-t细胞及其制备方法和应用 |
| CN111876432B (zh) * | 2020-07-29 | 2022-10-28 | 舒泰神（北京）生物制药股份有限公司 | 一组肝靶向新型腺相关病毒的获得及其应用 |
| KR20230043869A (ko) | 2020-08-07 | 2023-03-31 | 스페이스크래프트 세븐, 엘엘씨 | Aav 벡터를 사용한 플라코필린-2(pkp2) 유전자 요법 |
| US20220096606A1 (en) | 2020-09-09 | 2022-03-31 | Vertex Pharmaceuticals Incorporated | Compositions and Methods for Treatment of Duchenne Muscular Dystrophy |
| US12071633B2 (en) | 2020-10-13 | 2024-08-27 | Kriya Therapeutics, Inc. | Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer |
| US20220110970A1 (en) * | 2020-10-14 | 2022-04-14 | The Texas A&M University System | Engineered Extracellular Vesicle Delivery Systems and Uses Thereof |
| WO2022098933A1 (en) | 2020-11-06 | 2022-05-12 | Vertex Pharmaceuticals Incorporated | Compositions and methods for treatment of dm1 with slucas9 and sacas9 |
| KR102803305B1 (ko) * | 2020-11-25 | 2025-05-07 | 연세대학교 산학협력단 | 트랜스-스플라이싱 아데노-연관 바이러스 벡터를 포함하는 프라임에디팅용 조성물 |
| US20220238230A1 (en) * | 2021-01-15 | 2022-07-28 | Trustees Of Tufts College | Methods for modulating the function of biological regulatory networks in health and disease by exploiting their memory properties |
| TW202302848A (zh) | 2021-02-26 | 2023-01-16 | 美商維泰克斯製藥公司 | 以crispr/sacas9治療第1型肌強直性營養不良之組合物及方法 |
| EP4298221A1 (en) | 2021-02-26 | 2024-01-03 | Vertex Pharmaceuticals Incorporated | Compositions and methods for treatment of myotonic dystrophy type 1 with crispr/slucas9 |
| US20240165271A1 (en) | 2021-03-26 | 2024-05-23 | The Board Of Regents Of The University Of Texas System | Nucleotide editing to reframe dmd transcripts by base editing and prime editing |
| WO2022229851A1 (en) | 2021-04-26 | 2022-11-03 | Crispr Therapeutics Ag | Compositions and methods for using slucas9 scaffold sequences |
| WO2022234519A1 (en) | 2021-05-05 | 2022-11-10 | Crispr Therapeutics Ag | Compositions and methods for using sacas9 scaffold sequences |
| US20240252679A1 (en) | 2021-05-28 | 2024-08-01 | Shanghai Regenelead Therapies Co., Ltd. | Recombinant adeno-associated virus having variant capsid, and application thereof |
| WO2023280175A1 (en) * | 2021-07-06 | 2023-01-12 | National Institute Of Biological Sciences, Beijing | Methods for treating complex i deficiencies or cancers by modulating gro3p biosynthesis |
| WO2023018637A1 (en) | 2021-08-09 | 2023-02-16 | Vertex Pharmaceuticals Incorporated | Gene editing of regulatory elements |
| WO2023039444A2 (en) | 2021-09-08 | 2023-03-16 | Vertex Pharmaceuticals Incorporated | Precise excisions of portions of exon 51 for treatment of duchenne muscular dystrophy |
| US20240408240A1 (en) | 2021-10-01 | 2024-12-12 | Biomarin Pharmaceutical Inc. | Treatment of hereditary angioedema with aav gene therapy vectors and therapeutic formulations |
| EP4219726A1 (en) | 2021-10-15 | 2023-08-02 | Research Institute at Nationwide Children's Hospital | Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy |
| JP2024540987A (ja) | 2021-10-21 | 2024-11-06 | バーテックス ファーマシューティカルズ インコーポレイテッド | 低免疫細胞 |
| TW202325850A (zh) | 2021-11-29 | 2023-07-01 | 大陸商上海瑞宏迪醫藥有限公司 | Aadc、gdnf多核苷酸及其用於治療帕金森病 |
| AU2023220237A1 (en) | 2022-02-21 | 2024-08-15 | Shanghai Regenelead Therapies Co., Ltd | Vegf-binding molecule and pharmaceutical use thereof |
| GB202202628D0 (en) * | 2022-02-25 | 2022-04-13 | Babraham Inst | Novel use and method comprising IL-2 and a tissue- or organic-specific targeting moiety |
| WO2023172927A1 (en) | 2022-03-08 | 2023-09-14 | Vertex Pharmaceuticals Incorporated | Precise excisions of portions of exon 44, 50, and 53 for treatment of duchenne muscular dystrophy |
| WO2023172926A1 (en) | 2022-03-08 | 2023-09-14 | Vertex Pharmaceuticals Incorporated | Precise excisions of portions of exons for treatment of duchenne muscular dystrophy |
| AU2023255614A1 (en) | 2022-04-18 | 2024-10-24 | Vertex Pharmaceuticals Incorporated | Compositions and methods for enhancing aav therapy and decreasing tropism of aav to the liver. |
| CN118460618A (zh) * | 2022-04-19 | 2024-08-09 | 康霖生物科技（杭州）有限公司 | 一种用于遗传性凝血因子缺乏病治疗的核酸构建体 |
| EP4558634A1 (en) | 2022-07-18 | 2025-05-28 | Vertex Pharmaceuticals Incorporated | Tandem guide rnas (tg-rnas) and their use in genome editing |
| CN120380156A (zh) | 2022-09-22 | 2025-07-25 | 迪纳柯公司 | 用aav基因治疗载体治疗心肌病 |
| KR20260019521A (ko) | 2023-05-25 | 2026-02-10 | 주노 쎄러퓨티크스 인코퍼레이티드 | Aav 정제 방법 |
| TW202508610A (zh) | 2023-08-23 | 2025-03-01 | 大陸商上海瑞宏迪醫藥有限公司 | 醫藥組成物及其用途 |
| WO2025082618A1 (en) | 2023-10-20 | 2025-04-24 | Fuse Vectors Aps | In vitro parvovirus capsid manufacturing |
| WO2025106374A1 (en) | 2023-11-13 | 2025-05-22 | Juno Therapeutics, Inc. | Aav production method |
| WO2025214477A1 (en) | 2024-04-12 | 2025-10-16 | Skyline Therapeutics (Shanghai) Co., Ltd. | Treatment of genetic cardiomyopathies with aav gene therapy vectors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
| US6468524B1 (en) | 2000-03-22 | 2002-10-22 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | AAV4 vector and uses thereof |
| MX359371B (es) * | 2001-11-13 | 2018-09-25 | Univ Pennsylvania | Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo. |
| ES2525067T3 (es) * | 2005-04-07 | 2014-12-17 | The Trustees Of The University Of Pennsylvania | Método de incremento de la función de un vector de AAV |
| US7588772B2 (en) * | 2006-03-30 | 2009-09-15 | Board Of Trustees Of The Leland Stamford Junior University | AAV capsid library and AAV capsid proteins |
| EP2561073B1 (en) * | 2010-04-23 | 2016-08-24 | University of Massachusetts | Cns targeting aav vectors and methods of use thereof |
| US9175280B2 (en) * | 2010-10-12 | 2015-11-03 | Sangamo Biosciences, Inc. | Methods and compositions for treating hemophilia B |
| US9434928B2 (en) * | 2011-11-23 | 2016-09-06 | Nationwide Children's Hospital, Inc. | Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides |
| MX390848B (es) * | 2015-06-23 | 2025-03-21 | Childrens Hospital Philadelphia | Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos. |
-
2013
- 2013-02-19 MX MX2014009975A patent/MX367100B/es active IP Right Grant
- 2013-02-19 CN CN201380009944.9A patent/CN104520428B/zh active Active
- 2013-02-19 JP JP2014557867A patent/JP6373763B2/ja active Active
- 2013-02-19 SG SG11201404956PA patent/SG11201404956PA/en unknown
- 2013-02-19 EP EP13749822.6A patent/EP2814958B1/en active Active
- 2013-02-19 KR KR1020147025988A patent/KR102057540B1/ko active Active
- 2013-02-19 CA CA2864879A patent/CA2864879C/en active Active
- 2013-02-19 WO PCT/US2013/026695 patent/WO2013123503A1/en not_active Ceased
- 2013-02-19 BR BR112014020325A patent/BR112014020325A2/pt not_active Application Discontinuation
- 2013-02-19 ES ES13749822T patent/ES2752191T3/es active Active
- 2013-02-19 AU AU2013221212A patent/AU2013221212B2/en active Active
- 2013-02-19 US US14/378,886 patent/US20150111955A1/en not_active Abandoned
- 2013-02-19 RU RU2014137450A patent/RU2653444C2/ru active
-
2014
- 2014-08-14 IL IL234148A patent/IL234148B/en active IP Right Grant
- 2014-08-18 CL CL2014002198A patent/CL2014002198A1/es unknown
- 2014-08-18 ZA ZA2014/06065A patent/ZA201406065B/en unknown
-
2018
- 2018-04-12 JP JP2018076881A patent/JP2018121655A/ja active Pending
- 2018-07-25 US US16/045,619 patent/US11939590B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015509711A5 (https=) | ||
| IL276192A (en) | Different AAV and preparations, methods and uses for transferring genes to cells, organs and tissues | |
| RU2014137450A (ru) | Композиции вектора aav и способы переноса генов в клетки, органы и ткани | |
| KR102527259B1 (ko) | 스터퍼/필러 폴리누클레오티드 서열을 포함하는 벡터 및 사용 방법 | |
| JP2024073614A (ja) | プラスミドを用いないａａｖベクター産生細胞株 | |
| WO2025226891A1 (en) | Nucleic acid encoding ides | |
| HK1223849B (en) | Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues |